196 related articles for article (PubMed ID: 35464812)
1. Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol.
Clowse M; Fischer-Betz R; Nelson-Piercy C; Scheuerle AE; Stephan B; Dubinsky M; Kumke T; Kasliwal R; Lauwerys B; Förger F
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221087650. PubMed ID: 35464812
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database.
Clowse MEB; Scheuerle AE; Chambers C; Afzali A; Kimball AB; Cush JJ; Cooney M; Shaughnessy L; Vanderkelen M; Förger F
Arthritis Rheumatol; 2018 Sep; 70(9):1399-1407. PubMed ID: 29623679
[TBL] [Abstract][Full Text] [Related]
3. Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol.
Clowse ME; Wolf DC; Förger F; Cush JJ; Golembesky A; Shaughnessy L; De Cuyper D; Mahadevan U
J Rheumatol; 2015 Dec; 42(12):2270-8. PubMed ID: 26523031
[TBL] [Abstract][Full Text] [Related]
4. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.
Mariette X; Förger F; Abraham B; Flynn AD; Moltó A; Flipo RM; van Tubergen A; Shaughnessy L; Simpson J; Teil M; Helmer E; Wang M; Chakravarty EF
Ann Rheum Dis; 2018 Feb; 77(2):228-233. PubMed ID: 29030361
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy.
Marin J; Acosta Felquer ML; Soriano ER
Open Access Rheumatol; 2018; 10():33-41. PubMed ID: 29765257
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy.
Prieto-Peña D; Calderón-Goercke M; Adán A; Chamorro-López L; Maíz-Alonso O; De Dios-Jiménez Aberásturi JR; Veroz R; Blanco S; Martín-Santos JM; Navarro F; Gallego A; González-Suárez S; Conesa A; García-Valle A; Cordero-Coma M; Pardiñas-Barón N; Demetrio R; Calvo-Río V; Martínez-Taboada VM; Castañeda S; Hernández JL; González-Gay MA; Blanco R
Clin Exp Rheumatol; 2021; 39(1):105-114. PubMed ID: 33124565
[TBL] [Abstract][Full Text] [Related]
7. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
Harrold LR; Litman HJ; Saunders KC; Dandreo KJ; Gershenson B; Greenberg JD; Low R; Stark J; Suruki R; Jaganathan S; Kremer JM; Yassine M
Arthritis Res Ther; 2018 Jan; 20(1):2. PubMed ID: 29329557
[TBL] [Abstract][Full Text] [Related]
8. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study.
Clowse ME; Förger F; Hwang C; Thorp J; Dolhain RJ; van Tubergen A; Shaughnessy L; Simpson J; Teil M; Toublanc N; Wang M; Hale TW
Ann Rheum Dis; 2017 Nov; 76(11):1890-1896. PubMed ID: 28814432
[TBL] [Abstract][Full Text] [Related]
9. Certolizumab pegol for treating axial spondyloarthritis.
Desmarais J; Beier S; Deodhar A
Expert Opin Biol Ther; 2016 Aug; 16(8):1059-64. PubMed ID: 27366922
[TBL] [Abstract][Full Text] [Related]
10. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients.
Förger F; Zbinden A; Villiger PM
Joint Bone Spine; 2016 May; 83(3):341-3. PubMed ID: 26617214
[TBL] [Abstract][Full Text] [Related]
11. Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Stevenson M; Archer R; Stevens JW; Goka E; Clowes M; Scott DL; Young A
Pharmacoeconomics; 2017 Nov; 35(11):1141-1151. PubMed ID: 28550592
[TBL] [Abstract][Full Text] [Related]
12. Certolizumab Pegol in Plaque Psoriasis: Considerations for Pregnancy.
Strain J; Leis M; Lee KO; Fleming P
Skin Therapy Lett; 2021 Mar; 26(2):1-5. PubMed ID: 33769772
[TBL] [Abstract][Full Text] [Related]
13. Certolizumab pegol in the treatment of psoriasis: Real-life data.
Turkmen M; Dogan S
Dermatol Ther; 2021 May; 34(3):e14929. PubMed ID: 33665940
[TBL] [Abstract][Full Text] [Related]
14. Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants.
Eworuke E; Panucci G; Goulding M; Neuner R; Toh S
Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):296-304. PubMed ID: 30430682
[TBL] [Abstract][Full Text] [Related]
15. Certolizumab pegol for the treatment of rheumatoid arthritis.
Horton S; Walsh C; Emery P
Expert Opin Biol Ther; 2012 Feb; 12(2):235-49. PubMed ID: 22165979
[TBL] [Abstract][Full Text] [Related]
16. Prospectively-followed pregnancies in patients with inflammatory arthritis taking biological drugs: an Italian multicentre study.
Bazzani C; Scrivo R; Andreoli L; Baldissera E; Biggioggero M; Canti V; Gerosa M; Pontikaki I; Ramoni V; Trespidi L; Zatti S; Caporali R; Gorla R; Iannone F; Lojacono A; Meroni P; Montecucco C; Motta M; Sabbadini MG; Valesini G; Tincani A
Clin Exp Rheumatol; 2015; 33(5):688-93. PubMed ID: 26311348
[TBL] [Abstract][Full Text] [Related]
17. Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study.
Umezawa Y; Sakurai S; Hoshii N; Nakagawa H;
Dermatol Ther (Heidelb); 2021 Apr; 11(2):513-528. PubMed ID: 33606269
[TBL] [Abstract][Full Text] [Related]
18. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies.
Blauvelt A; Paul C; van de Kerkhof P; Warren RB; Gottlieb AB; Langley RG; Brock F; Arendt C; Boehnlein M; Lebwohl M; Reich K
Br J Dermatol; 2021 Apr; 184(4):640-651. PubMed ID: 32531798
[TBL] [Abstract][Full Text] [Related]
20. Certolizumab Pegol Treatment in Three Patients With Takayasu Arteritis.
Ataş N; Varan Ö; Babaoğlu H; Satiş H; Bilici Salman R; Tufan A
Arch Rheumatol; 2019 Sep; 34(3):357-362. PubMed ID: 31598605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
